A phase I trial of F 573 as a treatment for viral hepatitis.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2011
At a glance
- Drugs F 573 (Primary)
- Indications Viral hepatitis
- Focus Adverse reactions
- Sponsors GNI; Shanghai Genomics
- 01 Jul 2011 Shanghai Genomics filed an IND application for F 573 in China, according to a EpiCept Corporation media release.
- 28 Jul 2008 New trial record.